Quick Answer
DOT drug test results fall into five categories under 49 CFR Part 40: Negative, Positive, Adulterated, Substituted, and Invalid. No result reaches the employer without passing through Medical Review Officer (MRO) review first. Collectors do not interpret results — their role ends when the specimen is handed to the courier.
When a donor walks out of your collection site, you hand off the specimen and your paperwork — and in most cases, that’s the last you hear about it. But what actually happens to that specimen? Who reads the result? What do all those outcome codes mean — negative, positive, adulterated, substituted, invalid? And when does the result circle back to you?
Collectors who understand the full DOT drug testing process — not just their piece of it — are more accurate, more confident, and more hirable. This article covers every result outcome under 49 CFR Part 40 and explains exactly what each one means for the collector.
1. The Collector’s Role Ends at the Lab Door
Let’s get one thing straight before anything else: collectors do not interpret drug test results. That is not your job, and attempting to do so would violate federal protocol. Your role is to perform the specimen collection accurately, document the chain of custody on the Custody and Control Form (CCF), and hand off the sealed specimen to the courier or laboratory. Once that happens, your direct responsibility ends.
The federally mandated gatekeeper for all DOT drug test results is the Medical Review Officer (MRO) — a licensed physician who has completed specialized MRO training and is responsible for receiving, reviewing, and verifying laboratory results before they are reported to employers. No result — not even a laboratory-confirmed positive — goes to an employer without passing through the MRO first. This process is governed by 49 CFR Part 40, Subpart G.
Understanding this separation of roles is critical. The collector gathers the specimen. The lab analyzes it. The MRO verifies the result. The employer acts on it. Each step is distinct, and no one in the chain substitutes for anyone else.
2. What Happens After You Send the Specimen
After the specimen leaves your collection site, it goes to a DOT-certified laboratory — one certified by the Department of Health and Human Services (HHS) under the National Laboratory Certification Program. Here’s what happens at the lab:
- 1.
Initial immunoassay screen — the specimen is first screened using an immunoassay test, which checks for the presence of drug metabolites at or above federally established cutoff concentrations. This screen is fast and highly sensitive, but it is not definitive. A screen can produce false positives, which is why a second step is required.
- 2.
GC/MS confirmation testing — any specimen that tests non-negative on the immunoassay screen is sent through gas chromatography/mass spectrometry (GC/MS) or equivalent confirmatory testing. GC/MS is highly specific and identifies the exact drug compound present. A result is not confirmed positive until it passes this second analysis.
- 3.
Lab reports to MRO — once analysis is complete, the laboratory reports the result directly to the MRO. The MRO does not receive results directly from the collection site — the lab is the reporting party.
Timeline: Negative results typically turn around in 24–72 hours. Non-negative results take longer — the MRO verification process adds additional time, and complex cases (adulterated, substituted, or results requiring donor interview) can take several days to over a week before a final determination is made.
3. The Five Result Outcomes
Under 49 CFR Part 40, there are five possible result outcomes for a DOT urine drug test. Every collector should know all five — not just what they mean to the donor, but what they mean for you.
Negative
No prohibited substance was detected at or above the federal cutoff concentration. The MRO reports a negative result to the employer, who is then cleared to place the donor in a safety-sensitive position. This is by far the most common outcome — approximately 96% of all DOT-regulated drug tests return a negative result. The collector plays no further role once the specimen is handed off.
Positive
A prohibited substance was confirmed at or above the cutoff concentration. Before reporting to the employer, the MRO is required to contact the donor to discuss the result — the donor may have a legitimate medical explanation (a valid prescription, for example) that the MRO must evaluate. If the MRO verifies the result after that review, a positive is reported to the employer. The collector has no role in this process and is not informed of the result.
Adulterated
The laboratory detected a chemical in the specimen that is not expected in normal human urine and that interferes with the testing process. This indicates an attempt to tamper with the specimen by introducing a foreign substance. An adulterated result is reported to the MRO, who — after attempting to contact the donor for explanation — typically reports it as a refusal to test. Under DOT regulations, a refusal to test carries the same consequences as a verified positive result.
Substituted
The specimen’s creatinine concentration and specific gravity are both outside the physiological range consistent with normal human urine. Specifically, a substituted specimen has a creatinine below 2 mg/dL and a specific gravity below 1.0010 or above 1.0200. This indicates that what was submitted is not consistent with urine from a live human — the donor likely submitted a synthetic or non-urine liquid. Like adulterated results, a substituted specimen is treated as a refusal to test.
Invalid
Testing could not be completed because the laboratory identified an interfering substance or a result that was outside the lab’s ability to verify. Unlike adulterated or substituted results, an invalid result does not automatically mean tampering — it may result from an unusual specimen characteristic, a medical condition, or an unidentifiable substance in the urine. When the MRO receives an invalid result, they contact the donor to discuss a possible medical explanation. In most cases, the MRO orders a recollection under direct observation. This is where the result circles directly back to the collection site — and to you.
Note: some donors experiencing anxiety or nerves may have difficulty providing a specimen at all — a situation that can also lead to a shy bladder situation that feeds into this same recollection pathway.
4. What “Refusal to Test” Means for the Collector
A refusal-to-test determination carries serious consequences for the donor — equivalent to a positive result. But collectors need to understand that their own actions can contribute to a result challenge that implicates the collection process.
When an adulterated or substituted result is reported, the donor may challenge the finding. One of the first things reviewed in a challenge is the chain-of-custody record. If the CCF has errors — an incorrect specimen ID number, a missing seal signature, a temperature reading outside the acceptable range that wasn’t properly documented — the collection itself becomes suspect. A challenged collection can delay the final result determination, require your involvement as the collector, and in some cases lead to the test being cancelled.
This is precisely why meticulous chain-of-custody documentation is not paperwork busywork — it’s your professional protection. Every step of the CCF process, every seal, every signature exists so that the result can withstand scrutiny. Collectors who are sloppy with chain of custody documentation are the ones who end up in the middle of a compliance investigation.
5. MRO Verification Interview — What Collectors Should Know
The MRO’s job includes reviewing the CCF as part of the result verification process. In some cases — particularly when there are questions about the collection record — the MRO may contact the collector directly for clarification.
Here’s what collectors need to know about MRO contact:
Keep copies of your CCFs. Collectors are required to retain Copy 1 of the CCF (the lab’s copy goes with the specimen; Copy 2 goes to the MRO; Copy 4 goes to the donor; Copy 5 stays with the collector). If the MRO calls with a question about a collection you performed weeks ago, you need to be able to pull up that record and speak to it accurately.
Be reachable. The MRO may need to ask about handwriting clarification, a Remarks notation, or a procedural step. If you change employers or contact information, make sure your collection site has updated information on file.
The MRO will not share result values with you. Concentration levels — the exact amount of a substance detected in the specimen — are confidential and are not shared with the collector. The MRO is not authorized to disclose that information to collection site personnel. If an MRO contact asks about the collection, they are asking about the process, not the result. Do not ask about the result.
Answer factually and document the contact. If an MRO calls with a collection question, answer based on your CCF records, not from memory. Note the date, time, and content of the MRO’s inquiry for your own records.
6. Observed Recollection After Invalid Results
When the MRO orders a recollection after an invalid result, it is almost always ordered under direct observation. This means the next collection is not a standard, unobserved collection — a same-gender observer must directly watch the donor provide the specimen to ensure no tampering is possible.
That observer is the collector — or a collector designated by the collection site. The invalid result on the first collection leads directly to an observed collection at the second. If you don’t know how to conduct an observed collection correctly — who can serve as observer, how the observation is performed, how the CCF is annotated — the invalid result has now created a second collection that is also at risk.
This is the feedback loop that most collectors don’t think about until they’re in the middle of it. An invalid result isn’t just a lab issue — it comes back to your collection site with a more demanding procedure attached. Collectors who know the full process are ready for that. Collectors who only know the standard procedure are not.
7. Why Collectors Who Understand Results Are More Hirable
There’s a real professional gap between a collector who can execute the 45mL collection procedure and a collector who understands the entire DOT drug testing ecosystem. Employers know the difference. Third-Party Administrators (TPAs) who contract collection sites know the difference. And it shows up in hiring.
When a collection site is vetted for a TPA contract, one of the things evaluated is whether the collector team understands what happens to the specimens they collect. Can they explain what a substituted result means and why chain-of-custody documentation matters? Do they know what triggers a directly observed recollection? Can they describe the MRO’s role accurately? These aren’t obscure technical questions — they’re the baseline of professional competence in DOT-regulated collections.
A collector who watched a YouTube video on how to fill out a CCF is not the same as a collector who completed a structured certification course covering 49 CFR Part 40 from front to back. Employers and TPAs can tell which one they’re talking to — and they contract with the second.
If you’re ready to build that level of competence, the certification path is shorter than most people expect — and Cedar & Crown Collector Academy covers it end-to-end.